Base de dados : MEDLINE
Pesquisa : B01.300.107.795.785.400 [Categoria DeCS]
Referências encontradas : 26 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 26 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28732069
[Au] Autor:Brun P; Scarpa M; Marchiori C; Sarasin G; Caputi V; Porzionato A; Giron MC; Palù G; Castagliuolo I
[Ad] Endereço:Department of Molecular Medicine, University of Padova, Padova, Italy.
[Ti] Título:Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
[So] Source:PLoS One;12(7):e0181863, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscular anomalies in an IBS-type mouse model of gastrointestinal motor dysfunctions elicited by Herpes Simplex Virus type 1 (HSV-1) exposure. METHODS: Mice were inoculated intranasally with HSV-1 (102 PFU) or vehicle at time 0 and 4 weeks later by the intragastric (IG) route (108 PFU). Six weeks after IG inoculum, mice were randomly allocated to receive oral gavage with either S. boulardii (107 CFU/day) or vehicle. After 4 weeks the following were determined: a) intestinal motility using fluorescein-isothiocyanate dextran distribution in the gut, fecal pellet expulsion, stool water content, and distal colonic transit of glass beads; b) integrity of the enteric nervous system (ENS) by immunohistochemistry on ileal whole-mount preparations and western blot of protein lysates from ileal longitudinal muscle and myenteric plexus; c) isometric muscle tension with electric field and pharmacological (carbachol) stimulation of ileal segments; and d) intestinal inflammation by levels of tumor necrosis factor α, interleukin(IL)-1ß, IL-10 and IL-4. RESULTS: S. boulardii CNCM I-745 improved HSV-1 induced intestinal dysmotility and alteration of intestinal transit observed ten weeks after IG inoculum of the virus. Also, the probiotic yeast ameliorated the structural alterations of the ENS induced by HSV-1 (i.e., reduced peripherin immunoreactivity and expression, increased glial S100ß protein immunoreactivity and neuronal nitric oxide synthase level, reduced substance P-positive fibers). Moreover, S. boulardii CNCM I-745 diminished the production of HSV-1 associated pro-inflammatory cytokines in the myenteric plexus and increased levels of anti-inflammatory interleukins. CONCLUSIONS: S. boulardii CNCM I-745 ameliorated gastrointestinal neuromuscular anomalies in a mouse model of gut dysfunctions typically observed with irritable bowel syndrome.
[Mh] Termos MeSH primário: Motilidade Gastrointestinal/efeitos dos fármacos
Síndrome do Intestino Irritável/microbiologia
Síndrome do Intestino Irritável/terapia
Probióticos/farmacologia
Saccharomyces boulardii/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Animais
Colo/metabolismo
Colo/microbiologia
Colo/virologia
Citocinas/metabolismo
Diarreia/metabolismo
Diarreia/microbiologia
Diarreia/virologia
Modelos Animais de Doenças
Sistema Nervoso Entérico/metabolismo
Sistema Nervoso Entérico/microbiologia
Sistema Nervoso Entérico/virologia
Herpes Simples/metabolismo
Herpes Simples/microbiologia
Herpes Simples/virologia
Herpesvirus Humano 1/patogenicidade
Íleo/metabolismo
Íleo/microbiologia
Íleo/virologia
Inflamação/metabolismo
Inflamação/microbiologia
Inflamação/virologia
Interleucina-10/metabolismo
Interleucina-1beta/metabolismo
Interleucina-4/metabolismo
Síndrome do Intestino Irritável/metabolismo
Síndrome do Intestino Irritável/virologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Músculos/metabolismo
Músculos/microbiologia
Músculos/virologia
Plexo Mientérico/metabolismo
Plexo Mientérico/microbiologia
Plexo Mientérico/virologia
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Interleukin-1beta); 0 (Tumor Necrosis Factor-alpha); 130068-27-8 (Interleukin-10); 207137-56-2 (Interleukin-4)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171117
[Lr] Data última revisão:
171117
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181863


  2 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28592037
[Au] Autor:Zhang DM; Xu BB; Yu L; Zheng LF; Chen LP; Wang W
[Ti] Título:[A prospective control study of in prevention of antibiotic-associated diarrhea in the older inpatients].
[So] Source:Zhonghua Nei Ke Za Zhi;56(6):398-401, 2017 Jun 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To study the value of for the prevention of antibiotic-associated diarrhea in older inpatients. A total of 163 older patients who were treated with wide-spectrum antibiotics at least three days during January 2014 to December 2015 were randomly divided into control and study group. In study group, 81 patients were administrated with oral 500 mg twice a day for 21 days. The control group was of no intervention. Morbidity rate of antibiotic-associated diarrhea and -associated diarrhea, frequency and duration of diarrhea were recorded. The incidence of antibiotic-associated diarrhea in study group was significantly lower than that in control group [14.8%(12/81) vs 28.0%(23/82), <0.05], whereas no difference was seen in the incidence of -associated diarrhea [3.7%(3/81) vs 4.9%(4/82), >0.05] in two groups. The frequency and duration of diarrhea in the study group were significantly lower and shorter than those in control group[(4.3±1.7) times/day vs (6.9±2.0) times/day; (3.0±1.1) days vs (5.7±1.8) days, both <0.01]. may reduce the incidence of antibiotic-associated diarrhea therefore improving the symptom of diarrhea in older inpatients.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Clostridium difficile/patogenicidade
Diarreia/induzido quimicamente
Diarreia/prevenção & controle
Pacientes Internados/estatística & dados numéricos
Probióticos/uso terapêutico
Saccharomyces boulardii
[Mh] Termos MeSH secundário: Idoso
China/epidemiologia
Diarreia/epidemiologia
Feminino
Seres Humanos
Incidência
Masculino
Probióticos/administração & dosagem
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.06.003


  3 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28482385
[Au] Autor:Wan CM; Yu H; Liu G; Xu HM; Mao ZQ; Xu Y; Jin Y; Luo RP; Wang WJ; Fang F
[Ad] Endereço:West China Second University Hospital, Sichuan University, Chengdu 610041, China.
[Ti] Título:[A multicenter randomized controlled study of in the prevention of antibiotic-associated diarrhea in infants and young children].
[So] Source:Zhonghua Er Ke Za Zhi;55(5):349-354, 2017 May 04.
[Is] ISSN:0578-1310
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the efficacy and safety of in the prevention of antibiotic-associated diarrhea (AAD) in infants and young children. From November 2012 to September 2013, ten research units of large teaching hospitals or children's hospitals participated in this multicenter randomized controlled clinical trial. Hospitalized young children aged between 1 month and 3 years (nongastrointestinal infection and antibiotic therapy required)were involved in our study. The children were randomly divided into control group and prevention group by means of block random allocation method. The control group received antibiotic therapy and other conventional treatment. The prevention group was given additional (250 mg/d) orally. Diarrhea rates of two groups were compared both during the usage of antibiotics and within 14 days after the antibiotics withdrawal. The adverse reactions of were observed all through this study. The results were analyzed by χ(2) test or Kruskal-Wallis test or test. Totally 408 cases (213 cases in prevention group and 195 cases in control group) were enrolled. The age ranged from 1 month to 3 years, with an average age of 1.14 years. The basic diseases were parenteral infections: 368 cases with different kinds of respiratory tract infections or pneumonia, 10 cases of bacterial meningitis, 9 cases with septicemia or sepsis, 6 cases with pertussis or pertussis like syndrome, 5 cases with urinary infection, 5 cases with skin or subcutaneous tissue infections, 3 cases of Kawasaki disease, one with scarlet fever and one with congenital syphilis. During the administration of antibiotics, the incidence of AAD in prevention group was 10.3% (22 cases), which was significantly lower than that of control group (57 cases, 29.2%, χ(2)=23.296, <0.05). Within 14 days after the discontinuation of antibiotics, the percent of new diarrhea cases in prevention group (2.4%, 5/213) was also significantly lower than that in control group (16.4%, 32/195, χ(2)=23.4, <0.05). Further analysis revealed that the rate of AAD in children less than or equal to 1 year old (25.1%, 52/207) was significantly higher than that of over 1 year old (13.4%, 27/201, χ(2)=8.922, <0.05). The incidence of AAD in children treated with antibiotics for more than 5 days was 22.2%(60/270), which was significantly higher than that of less than or equal to 5 days (13.8%, 19/138, χ(2)=4.180, <0.05). Although no significant difference was observed, the AAD rate of patients with combined use of two antibiotics was higher than that of using one. During the antibiotic therapy, compared with the control group, the risk of AAD in children under 1 year old was reduced by 52% (χ(2)=9.217, <0.05), and 91% (χ(2)=20.35, <0.05) in the children over 1 year old in prevention group. The risk of AAD of prevention group decreased by 66% (χ(2)=13.67, <0.05) in patients treated with one antibiotics, and 65% in children with combined use of antibiotics (χ(2)=10.57, <0.05). In patients treated with antibiotics for less than or equal to 5 days, the risk of AAD decreased by 74% in prevention group (χ(2)=7.38, <0.05); and 63% if the course lasted for over 5 days (χ(2)=16.87, <0.05). Within 14 days after the withdrawal of antibiotics, compared with the control group, the risk of diarrhea in the prevention group decreased by 82% (χ(2)=13.35, <0.05) in infants (≤1 year old) and 93% (χ(2)=12.00, <0.05) in children (>1 year old); the risk of diarrhea was reduced by 86% (χ(2)=9.57, <0.05) and 87% (χ(2)=17.71, <0.05) respectively in prevention group with single and combined use of antibiotics. In patients treated with antibiotics for more than 5 days, the risk of diarrhea in prevention group was reduced by 63% (χ(2)=22.79, <0.05), while there was no significant difference if the antibiotics course was less than or equal to 5 days (χ(2)=2.97, >0.05). No adverse effects related with were observed in our study. is effective and safe to prevent AAD of infants and young children both during the usage of antibiotics and up to 14 days after drug discontinuance. It can be one of the drugs of for choice prevention of AAD in infants and young children. Trial registration Chinese Clinical Trial Tegister, ChiECRCT-2012-25.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Diarreia/prevenção & controle
Probióticos/uso terapêutico
Saccharomyces boulardii
[Mh] Termos MeSH secundário: Pré-Escolar
Feminino
Seres Humanos
Incidência
Lactente
Recém-Nascido
Masculino
Pneumonia/tratamento farmacológico
Infecções Respiratórias/tratamento farmacológico
Sepse
Coqueluche/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170509
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1310.2017.05.008


  4 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388647
[Au] Autor:Villar-García J; Güerri-Fernández R; Moya A; González A; Hernández JJ; Lerma E; Guelar A; Sorli L; Horcajada JP; Artacho A; D Auria G; Knobel H
[Ad] Endereço:Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
[Ti] Título:Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
[So] Source:PLoS One;12(4):e0173802, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic Saccharomyces boulardii significantly reduced plasma levels of bacterial translocation (Lipopolysaccharide-binding protein or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immunologic non-response to antiretroviral therapy (<270 CD4+Tcells/µL despite long-term suppressed viral load). The aim of the present study was to investigate if this beneficial effect of the probiotic Saccharomyces boulardii is due to modified gut microbiome composition, with a decrease of some species associated with higher systemic levels of microbial translocation and inflammation. In this study, we used 16S rDNA gene amplification and parallel sequencing to analyze the probiotic impact on the composition of the gut microbiome (faecal samples) in these 44 patients randomized to receive oral supplementation with probiotic or placebo for 12 weeks. Compared to the placebo group, in individuals treated with probiotic we observed lower concentrations of some gut species, such as those of the Clostridiaceae family, which were correlated with systemic levels of bacterial translocation and inflammation markers. In a sub-study of these patients, we observed significantly higher parameters of microbial translocation (LBP, soluble CD14) and systemic inflammation in immunologic non-responders than in immunologic responders, which was correlated with a relative abundance of specific gut bacterial groups (Lachnospiraceae genus and Proteobacteria). Thus, in this work, we propose a new therapeutic strategy using the probiotic yeast S. boulardii to modify gut microbiome composition. Identifying pro-inflammatory species in the gut microbiome could also be a useful new marker of poor immune response and a new therapeutic target.
[Mh] Termos MeSH primário: Infecções por HIV/microbiologia
Intestinos/microbiologia
Microbiota
Probióticos
Saccharomyces boulardii
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Placebos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placebos)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0173802


  5 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28319123
[Au] Autor:Rajput IR; Ying H; Yajing S; Arain MA; Weifen L; Ping L; Bloch DM; Wenhua L
[Ad] Endereço:College of Science Shantou University, Shantou, Guangdong, P.R. China.
[Ti] Título:Saccharomyces boulardii and Bacillus subtilis B10 modulate TLRs and cytokines expression patterns in jejunum and ileum of broilers.
[So] Source:PLoS One;12(3):e0173917, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The present study was designed to evaluate the effects of Saccharomyces boulardii (Sb) and Bacillus subtilis B10 (Bs) on intestinal epithelial Toll like receptors (TLR), and Cytokine expression response to understand the intestinal epithelial innate immune mechanism in broilers. A total of 300 birds (Sanhuang broilers) were allotted into three groups (n = 100) and each divided into five replications (n = 20). Control group (Ctr) birds were fed basal diet, broilers in experimental groups received (1×108cfu/kg feed) Sb and Bs respectively in addition to basal diet for 72 days. The result showed significant increase in mRNA expression level of TLR2, TLR4 and TLR15. Down streaming MyD88, TRAF6, TAB2 and NF-κB mRNA level noted higher, in the jejunum and ileum as compared to control group. Meanwhile, IL-6, TNFα, IL-10, TGF-ß expression levels showed high expression in the jejunum of Sb and Bs groups. IL-10 expression level increased in the ileum and IL-6, TNFα, IL-10 and TGF-ß expression levels increased in the jejunum of Sb group. Levels of IL-1 ß, IL-17, and IL-4, increased merely in Sb group. Ileal cytokines IL-1ß, IL-17 and IL-4concentration were noted higher in Sb group, and IL-1ß, and IL-4 levels were up-regulated in Bs group. The results indicated that the INF-γ and IL-8 level decreased in Sb and BS groups. Serum IgA and sIgA level increased in both treatment groups. Our findings illustrated that S. boulardii and B. subtilis B10 may have a role to induce mucosal immunity by activating the TLRs and cytokines expressions in broilers.
[Mh] Termos MeSH primário: Bacillus subtilis/fisiologia
Citocinas/genética
Regulação da Expressão Gênica
Íleo/metabolismo
Jejuno/metabolismo
Saccharomyces boulardii/fisiologia
Receptores Toll-Like/genética
[Mh] Termos MeSH secundário: Animais
Galinhas
Citocinas/biossíntese
Regulação da Expressão Gênica/efeitos dos fármacos
Íleo/efeitos dos fármacos
Íleo/microbiologia
Imunoglobulina A/sangue
Imunoglobulina A/metabolismo
Jejuno/efeitos dos fármacos
Jejuno/microbiologia
Probióticos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Immunoglobulin A); 0 (Toll-Like Receptors)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0173917


  6 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28188340
[Au] Autor:Fleury MA; Le Goff O; Denis S; Chaucheyras-Durand F; Jouy E; Kempf I; Alric M; Blanquet-Diot S
[Ad] Endereço:UMR UCA INRA 454 MEDIS, Centre de Recherche en Nutrition Humaine, Université Clermont Auvergne, 63000, Clermont-Ferrand, France.
[Ti] Título:Development and validation of a new dynamic in vitro model of the piglet colon (PigutIVM): application to the study of probiotics.
[So] Source:Appl Microbiol Biotechnol;101(6):2533-2547, 2017 Mar.
[Is] ISSN:1432-0614
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:For ethical, technical, regulatory, and cost reasons, in vitro methods are increasingly used as an alternative to in vivo experimentations. The aim of the present study was to validate, according to in vivo data in living animals, a new in vitro model of the piglet colon, the PigutIVM, under both control conditions and antibiotic disturbance by the widely used colistin. The PigutIVM reproduces the main biotic and abiotic parameters of the piglet colon: temperature, pH, retention time, supply of ileal effluents, complex, and metabolically active microbiota and self-maintained anaerobiosis. Under both control and antibiotic-treated conditions, qPCR analyses showed that the main bacterial populations of piglet gut microbiota were similar in vitro and in vivo, with Pearson correlation coefficient higher than 0.9. During colistin administration, both in piglets and in the in vitro model, a significant decrease in Escherichia coli populations was observed together with changes in microbial composition of subdominant populations. SCFA concentrations were similar in vitro and in vivo and were not modified by colistin. Interestingly, the administration of the probiotic Saccharomyces cerevisiae var. boulardii CNCM I-1079 led in vitro to a decrease in E. coli levels, as previously observed when the antibiotic treatment was applied. This new in vitro model of the piglet colon provides a flexible, reproducible, and cost-effective tool for the screening of drugs or new dietary compounds, such as pre- or probiotics. It will be helpful for researchers, feed producers, or veterinarians when developing innovative non-antibiotic strategies.
[Mh] Termos MeSH primário: Reatores Biológicos
Cultura em Câmaras de Difusão
Microbioma Gastrointestinal/efeitos dos fármacos
Consórcios Microbianos/efeitos dos fármacos
Probióticos/farmacologia
[Mh] Termos MeSH secundário: Anaerobiose
Animais
Antibacterianos/farmacologia
Colistina/farmacologia
Colo/efeitos dos fármacos
Colo/microbiologia
Escherichia coli/efeitos dos fármacos
Escherichia coli/crescimento & desenvolvimento
Fezes/microbiologia
Microbioma Gastrointestinal/fisiologia
Concentração de Íons de Hidrogênio
Íleo/efeitos dos fármacos
Íleo/microbiologia
Consórcios Microbianos/fisiologia
Modelos Biológicos
Saccharomyces boulardii/efeitos dos fármacos
Saccharomyces boulardii/crescimento & desenvolvimento
Suínos
Temperatura Ambiente
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170307
[Lr] Data última revisão:
170307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170212
[St] Status:MEDLINE
[do] DOI:10.1007/s00253-017-8122-y


  7 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28133894
[Au] Autor:Roy U; Jessani LG; Rudramurthy SM; Gopalakrishnan R; Dutta S; Chakravarty C; Jillwin J; Chakrabarti A
[Ad] Endereço:Apollo Gleneagles Hospitals, Kolkata, India.
[Ti] Título:Seven cases of Saccharomyces fungaemia related to use of probiotics.
[So] Source:Mycoses;60(6):375-380, 2017 Jun.
[Is] ISSN:1439-0507
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Probiotics are increasingly used in critically ill patients without enough safety data. The aim of the present study was to determine the association of probiotics with Saccharomyces cerevisiae fungaemia. Seven patients with S. cerevisiae fungaemia were reported at two hospitals in India between July 2014 and September 2015. Detailed clinical history of patients was recorded. Besides the seven patient isolates, three probiotics sachets used in those patients and five unrelated clinical isolates were used for association study by Fluorescent amplified fragment length polymorphism (FAFLP). Antifungal susceptibility testing was performed by broth microdilution technique of CLSI (M27-A3) and interpreted according to CLSI (M27S4). Two patients were premature neonates and five were adults. They were admitted in intensive care unit and were on probiotics containing S. boulardii (except one adult patient). FAFLP analysis showed 96.4-99.7% similarity between blood and corresponding probiotic isolates. Of the three AFLP types (group I, II, II) identified, all the probiotic isolates clustered in group I (major cluster) including majority of the blood isolates. The isolates were susceptible to all antifungal agents tested. Five patients, who could be evaluated, responded promptly to echinocandins or voriconazole. As the prescription of probiotic containing S. boulardii in critically ill patient's leads to the fungaemia, we recommend avoiding this probiotic in those patients.
[Mh] Termos MeSH primário: Fungemia/diagnóstico
Probióticos/efeitos adversos
Saccharomyces cerevisiae/isolamento & purificação
[Mh] Termos MeSH secundário: Adulto
Idoso
Análise do Polimorfismo de Comprimento de Fragmentos Amplificados
Antifúngicos/uso terapêutico
Estado Terminal/terapia
Farmacorresistência Fúngica
Equinocandinas/uso terapêutico
Feminino
Fungemia/tratamento farmacológico
Fungemia/microbiologia
Seres Humanos
Índia
Recém-Nascido
Masculino
Testes de Sensibilidade Microbiana
Família Multigênica
Probióticos/administração & dosagem
RNA Ribossômico/genética
Saccharomyces boulardii/isolamento & purificação
Voriconazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Echinocandins); 0 (RNA, Ribosomal); 0 (RNA, ribosomal, 26S); JFU09I87TR (Voriconazole)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170131
[St] Status:MEDLINE
[do] DOI:10.1111/myc.12604


  8 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28024866
[Au] Autor:Martin IW; Tonner R; Trivedi J; Miller H; Lee R; Liang X; Rotello L; Isenbergh E; Anderson J; Perl T; Zhang SX
[Ad] Endereço:Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
[Ti] Título:Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use.
[So] Source:Diagn Microbiol Infect Dis;87(3):286-288, 2017 Mar.
[Is] ISSN:1879-0070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report a case of fungemia in an immunocompetent patient after administration of probiotic containing Saccharomyces boulardii. We demonstrated the strain relatedness of the yeast from the probiotic capsule and the yeast causing fungal infection using genomic and proteomic typing methods. Our study questions the safety of this preventative biotherapy.
[Mh] Termos MeSH primário: Fungemia/tratamento farmacológico
Fungemia/microbiologia
Probióticos/efeitos adversos
Saccharomyces boulardii/isolamento & purificação
[Mh] Termos MeSH secundário: Antifúngicos/uso terapêutico
Diarreia/tratamento farmacológico
Diarreia/prevenção & controle
Fluconazol/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Técnicas de Tipagem Micológica
Probióticos/uso terapêutico
Pirimidinas/uso terapêutico
Sulfonamidas/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Pyrimidines); 0 (Sulfonamides); 00A64ZX8NB (florasulam); 8VZV102JFY (Fluconazole)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170217
[Lr] Data última revisão:
170217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE


  9 / 26 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28008823
[Au] Autor:Silveira MM; Conceição FR; Mendonça M; Moreira GM; Da Cunha CE; Conrad NL; Oliveira PD; Hartwig DD; De Leon PM; Moreira ÂN
[Ad] Endereço:1​Programa de Pós-Graduação em Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Campus Universitário S/N, Caixa Postal 354, 96010-900 Pelotas, RS, Brazil.
[Ti] Título:Saccharomyces boulardii improves humoral immune response to DNA vaccines against leptospirosis.
[So] Source:J Med Microbiol;66(2):184-190, 2017 Feb.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Saccharomyces boulardii may improve the immune response by enhancing the production of anti-inflammatory cytokines, T-cell proliferation and dendritic cell activation. The immunomodulator effect of this probiotic has never been tested with DNA vaccines, which frequently induce low antibody titers. This study evaluated the capacity of Saccharomyces boulardii to improve the humoral and cellular immune responses using DNA vaccines coding for the leptospiral protein fragments LigAni and LigBrep. BALB/c mice were fed with rodent-specific feed containing 108 c.f.u. of Saccharomycesboulardii per gram. METHODOLOGY: Animals were immunized three times intramuscularly with 100 µg of pTARGET plasmids containing the coding sequences for the above mentioned proteins. Antibody titers were measured by indirect ELISA. Expression levels of IL-4, IL-10, IL-12, IL-17, IFN-γ and TGF-ß were determined by quantitative real-time PCR from RNA extracted from whole blood, after an intraperitoneal boost with 50 µg of the recombinant proteins.Results/Key findings. Antibody titers increased significantly after the second and third application when pTARGET/ligAni and pTARGET/ligBrep were used to vaccinate the animals in comparison with the control group (P<0.05). In addition, there was a significant increase in the expression of the IL-10 in mice immunized with pTARGET/ligBrep and fed with Saccharomyces boulardii. CONCLUSION: The results suggested that Saccharomyces boulardii has an immunomodulator effect in DNA vaccines, mainly by stimulating the humoral response, which is often limited in this kind of vaccine. Therefore, the use of Saccharomyces boulardii as immunomodulator represents a new alternative strategy for more efficient DNA vaccination.
[Mh] Termos MeSH primário: Vacinas Bacterianas/imunologia
Imunidade Humoral
Leptospirose/imunologia
Saccharomyces boulardii
Vacinas de DNA/imunologia
[Mh] Termos MeSH secundário: Animais
Proteínas de Bactérias/genética
Citocinas/genética
Citocinas/metabolismo
Escherichia coli/genética
Escherichia coli/metabolismo
Feminino
Fatores Imunológicos/imunologia
Leptospira
Leptospirose/prevenção & controle
Camundongos
Camundongos Endogâmicos BALB C
Probióticos/administração & dosagem
Proteínas Recombinantes/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Bacterial Vaccines); 0 (Cytokines); 0 (Immunologic Factors); 0 (Recombinant Proteins); 0 (Vaccines, DNA)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170315
[Lr] Data última revisão:
170315
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000414


  10 / 26 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27973989
[Au] Autor:Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
[Ad] Endereço:a Division of Gastroenterology, Department of Medicine , Beth Israel Deaconess Medical Center , Boston , MA , USA.
[Ti] Título:Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
[So] Source:Gut Microbes;8(1):17-32, 2017 Jan 02.
[Is] ISSN:1949-0984
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Probiotics are believed to be beneficial in maintaining a healthy gut microbiota whereas antibiotics are known to induce dysbiosis. This study aimed to examine the effects of the probiotic Saccharomyces boulardii CNCM I-745 (SB), the antibiotic Amoxicillin-Clavulanate (AC) and the combination on the microbiota and symptoms of healthy humans. Healthy subjects were randomized to one of 4 study groups: SB for 14 days, AC for 7 days, SB plus AC, Control (no treatment). Participants gave stool samples and completed gastro-intestinal symptom questionnaires. Microbiota changes in stool specimens were analyzed using 16s rRNA gene pyrosequencing (bTEFAP). Only one subject withdrew prematurely due to adverse events. Subjects treated by S boulardii + AC had fewer adverse events and tolerated the study regimen better than those receiving the AC alone. Control subjects had a stable microbiota throughout the study period. Significant microbiota changes were noted in the AC alone group during antibiotic treatment. AC associated changes included reduced prevalence of the genus Roseburia and increases in Escherichia, Parabacteroides, and Enterobacter. Microbiota alterations reverted toward baseline, but were not yet completely restored 2 weeks after antibiotherapy. No significant shifts in bacterial genera were noted in the SB alone group. Adding SB to AC led to less pronounced microbiota shifts including less overgrowth of Escherichia and to a reduction in antibiotic-associated diarrhea scores. Antibiotic treatment is associated with marked microbiota changes with both reductions and increases in different genera. S. boulardii treatment can mitigate some antibiotic-induced microbiota changes (dysbiosis) and can also reduce antibiotic-associated diarrhea.
[Mh] Termos MeSH primário: Amoxicilina/administração & dosagem
Antibacterianos/administração & dosagem
Bactérias/efeitos dos fármacos
Ácido Clavulânico/administração & dosagem
Microbioma Gastrointestinal/efeitos dos fármacos
Probióticos/administração & dosagem
Saccharomyces boulardii/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Bactérias/classificação
Bactérias/genética
Bactérias/isolamento & purificação
Fezes/microbiologia
Feminino
Trato Gastrointestinal/microbiologia
Voluntários Saudáveis
Seres Humanos
Masculino
Meia-Idade
Saccharomyces boulardii/fisiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 23521W1S24 (Clavulanic Acid); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161216
[St] Status:MEDLINE
[do] DOI:10.1080/19490976.2016.1267890



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde